Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase 1/2 2Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 58Gastrointestinal 33Tumor-Agnostic 18Head & Neck 16Other solid neoplasm 14CNS 12Sarcoma 10Breast 8Genitourinary 5Lymphoid 4Gynecologic 3Plasma cell 2Dermatologic 2Other neoplasm 1Other hematologic neoplasm 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Ependymoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Erlotinib Hydrochloride × Gynecologic × Clear all
NCT00428194 2017-11-29

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Masonic Cancer Center, University of Minnesota

Phase 1 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00030498 2013-01-16

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
75 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Ependymoma, Esophageal Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Breast Neoplasms, Male

NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡